{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gout+Chronic",
    "query": {
      "condition": "Gout Chronic"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 40,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gout+Chronic&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:13:17.227Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06439602",
      "title": "Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gout",
        "Arthritis, Gouty",
        "Hyperuricemia",
        "Gout Chronic"
      ],
      "interventions": [
        {
          "name": "AR882 50 mg",
          "type": "DRUG"
        },
        {
          "name": "AR882 75 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arthrosi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 818,
      "start_date": "2024-06-26",
      "completion_date": "2026-04-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T04:13:17.227Z",
      "location_count": 52,
      "location_summary": "Foley, Alabama • Anchorage, Alaska • Peoria, Arizona + 47 more",
      "locations": [
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06439602"
    },
    {
      "nct_id": "NCT01356498",
      "title": "Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "pegloticase",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Savient Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2006-12",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2011-12-02",
      "last_synced_at": "2026-05-22T04:13:17.227Z",
      "location_count": 22,
      "location_summary": "San Francisco, California • Santa Maria, California • Whittier, California + 19 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01356498"
    },
    {
      "nct_id": "NCT03226899",
      "title": "A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gout",
        "Chronic Kidney Disease (CKD)"
      ],
      "interventions": [
        {
          "name": "Lesinurad",
          "type": "DRUG"
        },
        {
          "name": "XOI",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "colchicine",
          "type": "DRUG"
        },
        {
          "name": "corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ironwood Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 242,
      "start_date": "2017-07-19",
      "completion_date": "2019-02-25",
      "has_results": true,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-05-22T04:13:17.227Z",
      "location_count": 70,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03226899"
    },
    {
      "nct_id": "NCT04849312",
      "title": "Prediction of 30-Day Readmission Using Machine Learning",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Infection",
        "Heart Failure",
        "Chronic Obstructive Pulmonary Disease",
        "Asthma",
        "Gout Flare",
        "Chronic Kidney Diseases",
        "Hypertensive Urgency",
        "Atrial Fibrillation Rapid",
        "Anticoagulants; Increased"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 372,
      "start_date": "2017-06-01",
      "completion_date": "2019-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-05-22T04:13:17.227Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04849312"
    },
    {
      "nct_id": "NCT03303989",
      "title": "REduCing Immunogenicity to PegloticasE (RECIPE) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout Chronic"
      ],
      "interventions": [
        {
          "name": "Pegloticase 8 MG/ML [Krystexxa]",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2018-06-14",
      "completion_date": "2021-03-31",
      "has_results": true,
      "last_update_posted_date": "2022-03-16",
      "last_synced_at": "2026-05-22T04:13:17.227Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03303989"
    },
    {
      "nct_id": "NCT05045742",
      "title": "Prediction of Patient Deterioration Using Machine Learning",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Infection",
        "Heart Failure",
        "Chronic Obstructive Pulmonary Disease",
        "Asthma",
        "Gout Flare",
        "Chronic Kidney Diseases",
        "Hypertensive Urgency",
        "Atrial Fibrillation Rapid",
        "Anticoagulants; Increased"
      ],
      "interventions": [
        {
          "name": "Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 526,
      "start_date": "2021-03-20",
      "completion_date": "2026-02-16",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-05-22T04:13:17.227Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05045742"
    },
    {
      "nct_id": "NCT05256303",
      "title": "Rural Hospital-Level Care at Home for Acutely Ill Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Infections",
        "Heart Failure",
        "Chronic Obstructive Pulmonary Disease",
        "Asthma",
        "Gout Flare",
        "Chronic Kidney Diseases",
        "Hypertensive Urgency",
        "Atrial Fibrillation Rapid",
        "Anticoagulation",
        "Diabetes and Its Complications",
        "End of Life/Desires Only Medical Management"
      ],
      "interventions": [
        {
          "name": "Home Hospital care",
          "type": "OTHER"
        },
        {
          "name": "Traditional Hospital care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2022-02-16",
      "completion_date": "2024-01-17",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-05-22T04:13:17.227Z",
      "location_count": 2,
      "location_summary": "Quincy, Illinois • Hazard, Kentucky",
      "locations": [
        {
          "city": "Quincy",
          "state": "Illinois"
        },
        {
          "city": "Hazard",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05256303"
    },
    {
      "nct_id": "NCT04784351",
      "title": "Prediction of Expected Length of Hospital Stay Using Machine Learning",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Infection",
        "Heart Failure",
        "Chronic Obstructive Pulmonary Disease",
        "Asthma",
        "Gout Flare",
        "Chronic Kidney Diseases",
        "Hypertensive Urgency",
        "Atrial Fibrillation Rapid",
        "Anticoagulants; Increased"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-03-20",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-05-22T04:13:17.227Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04784351"
    },
    {
      "nct_id": "NCT03905512",
      "title": "A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Gout"
      ],
      "interventions": [
        {
          "name": "SEL-212",
          "type": "DRUG"
        },
        {
          "name": "KRYSTEXXA®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Selecta Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 170,
      "start_date": "2019-05-07",
      "completion_date": "2020-08-05",
      "has_results": true,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-05-22T04:13:17.227Z",
      "location_count": 43,
      "location_summary": "Anniston, Alabama • Sun City, Arizona • Little Rock, Arkansas + 35 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03905512"
    },
    {
      "nct_id": "NCT05119686",
      "title": "Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout",
        "Arthritis, Gouty",
        "Hyperuricemia",
        "Gout Chronic"
      ],
      "interventions": [
        {
          "name": "AR882 Dose 1",
          "type": "DRUG"
        },
        {
          "name": "AR882 Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arthrosi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 140,
      "start_date": "2021-11-16",
      "completion_date": "2022-11-17",
      "has_results": false,
      "last_update_posted_date": "2023-05-12",
      "last_synced_at": "2026-05-22T04:13:17.227Z",
      "location_count": 16,
      "location_summary": "Gilbert, Arizona • Sun City, Arizona • Tucson, Arizona + 12 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05119686"
    }
  ]
}